STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3180 by analyst upside · 2026-08-12
RMD
ResMed Inc.
Healthcare · Market Cap $33B · P/E 21.6x
ANALYST PRICE TARGET
+9.9%
implied upside to consensus target
Current Price $224.84
Consensus Target $247.2
Bull Target $325.0
Bear Target $175.0
Analysts Covering 15
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
5
Hold
8
Sell
1
52-Week Low $180.27
52-Week High $293.81
YTD Return -7.7%
FUNDAMENTALS
Market Cap $33B
P/E Ratio (TTM) 21.6x
Forward P/E 17.0x
EPS (TTM) $10.43
PEG Ratio 1.32
Dividend Yield 1.20%
Revenue (TTM) $5.7B
Profit Margin 26.9%
52-WEEK RANGE
52-Week Low $180.27
52-Week High $293.81
Current Price $224.84
Bear Target $175.0
Bull Target $325.0
● Now $224.84 ● Target $247.2
TRADING DATA
Avg Volume 1.5M
YTD Return -7.7%
Analyst Count 15
Consensus Hold
Upside to Target +9.9%
Last Updated 2026-08-12

ANALYST SUMMARY

ResMed Inc. (RMD) is currently trading at $224.84 with a Wall Street consensus price target of $247.2, implying potential upside of 9.9% over the next 12 months. 15 analysts currently cover RMD, with a consensus rating of Hold - 40% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $325.0, while the most cautious has a target of $175.0.

RMD operates in the Healthcare sector with a market capitalisation of $33B. The stock is down 7.7% year-to-date and is currently trading near the lower end of its 52-week range of $180.27 – $293.81.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RMD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Morgan Stanley ↓ Downgrade
Overweight → Equal-Weight 2026-06-17 Building track record
Citigroup - Reiterated
Buy → Buy 2026-06-15 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-05-01 Building track record
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-05-01 Building track record
Keybanc - Reiterated
Overweight → Overweight 2026-04-27 Building track record
Citigroup - Reiterated
Buy → Buy 2026-04-09 Building track record
Citigroup - Reiterated
Buy → Buy 2026-02-02 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-01-30 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
21/30
Consensus clarity
17/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →